Researchers from the University of Edinburgh and Heriot-Watt University in the UK have developed a medical camera that could see through the human body and track endoscopic tools used to evaluate internal conditions.
US regulators have placed on hold studies of French drugmaker Cellectis’ CAR-T therapy following a patient fatality.
A collaboration to develop next generation chimeric antigen receptor T cell therapy (CAR-T) (RELATED: Kite begins EU trial of CAR–T therapy) was announced by Takeda Pharmaceutical Company Limited (TSE: 4502) and Noile-Immune Biotech Inc..
The US Food and Drug Administration (FDA) has cleared Adherium for its new inhaler monitoring device for AstraZeneca’s Symbicort aerosol inhaler.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Gazyva® (obinutuzumab) in combination with chemotherapy followed by Gazyva alone for people with previously untreated follicular lymphoma, one of the most common blood cancers among adults. Follicular lymphoma, a slow-growing (indolent) form of non-Hodgkin’s lymphoma, is incurable and characterized by cycles of remission and relapse.
Apollo Endosurgery has received CE-Mark for its ORBERA365 Managed Weight Loss System allowing commercialisation in the European Union (EU) and member countries of the European Economic Area.
Medical technology firm Hologic has introduced new Brevera breast biopsy system with CorLumina imaging technology in the US.
Diagnostics company LabCorp (NYSE:LH) said today that it has closed its $1.2 billion acquisition of contract research organization Chiltern International.
Pediatric Neurology 2017 will focus on the latest and exodus innovations in all areas of Pediatric neurology research which offers exclusive opportunity for investigators across the globe to meet, network, and perceive new scientific innovations. This year's annual congress highlights the theme, "Channelizing the novel ideas for treating Pediatric Neurological Disorders" which reflects the innovative progress in Pediatric Neurology research.
Teva’s Austedo is now the first and only therapy approved in the US to treat both tardive dyskinesia and chorea associated with Huntington’s disease.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.